Skip to Main Content

Molecular Medicine, Pharmacology, and Physiology (MMPP) Track

MMPP Track Leadership

Faculty

  • Associate Professor of Psychiatry

    Research Interests
    • Behavioral Sciences
    • Electrochemistry
    • Neurobiology
    • Psychiatry
    • Signal Transduction
    • Substance-Related Disorders

    Nii Addy is an Associate Professor of Psychiatry and of Cellular and Molecular Physiology. He received his B.S. in Biology from Duke University and his Ph.D. in Neuroscience from Yale University. Dr. Addy directs a federally funded research program investigating cholinergic, dopaminergic and L-type calcium channel mechanisms mediating substance use and mood disorders. Dr. Addy’s team also studies the ability of tobacco product flavor additives to alter nicotine use behavior and addiction. He serves on the journal editorial board of Neuropsychopharmacology, Biological PsychiatryNicotine & Tobacco Research, and Neuropharmacology, and is a grant reviewer for the Neurobiology of Motivated Behavior (NMB) Study Section of the National Institutes of Health's Center for Scientific Review (CSR). Dr. Addy currently serves as the inaugural Director of Scientist Diversity and Inclusion at the Yale School of Medicine, as the Director of the faculty mentoring program for the Yale Minority Organization for Retention and Expansion (MORE), and as Co-chair of the Career Development Subcommittee of the Anti-Racism Task Force in the Yale Department of Psychiatry. He also contributes to graduate student and postdoctoral training and to diversity, equity, and inclusion initiatives through his efforts on campus and in scientific societies.

    In addition to his campus work, Dr. Addy hosts the Addy Hour podcast, discussing topics at the intersection of neuroscience, mental health, faith, culture and social justice. Episodes include dynamic conversations based on the lived experience and professional expertise of his guests - which include community leaders, clinicians and mental health experts, scientists, professional athletes and entertainers, faith leaders, and mental health advocates. As the creator and host of town hall community events, Dr. Addy has also built unique partnerships to encourage and equip audiences to embrace the use of holistic, integrated tools to address mental health challenges. He has collaborated with Lecrae (Grammy Award-winning artist and NY Times Best Seller), Doug Middleton (Jacksonville Jaguars/ Dream the Impossible Initiative), Allan Houston (former NBA All-Star, NY Knicks/ FISLL Project), the National Alliance on Mental Illness (NAMI), the Veritas Forum, the Anxiety and Depression Association of America (ADAA), the Association for Behavioral and Cognitive Therapies (ABCT), the Yale University Chaplain's Office, Yale Well, the Salvation Army, Every Nation Church NYC, the American Bible Society and others. His research and community work have been featured by National Public Radio (NPR), Newsday, the National Football League Players Association (NFLPA), The Source Magazine, Chuck Norris, BoldTV, Legitimate Matters, and Relevant Magazine. He has presented scientific lectures at universities throughout the United States and Europe, and he serves on the Board of Trustees for The Carver Project, aimed at empowering and connecting individuals across university, church and society.

  • William H. Carmalt Professor of Surgery; Chair, Department of Surgery; Interim Director, Yale Cancer Center; Interim Physician-in-Chief, Smilow Cancer Hospital

    Research Interests
    • Gastrointestinal Diseases
    • Pancreatic Neoplasms
    • Colorectal Neoplasms

    Nita Ahuja, MD, MBA, is the chair of the Department of Surgery at Yale School of Medicine and chief of surgery at Yale New Haven Hospital, effective February 1, 2018. Watch a video with Dr. Nita Ahuja>>

    Dr. Ahuja obtained her medical education at the Duke University School of Medicine and her training in general surgery at Johns Hopkins. She completed a fellowship in surgical oncology at Johns Hopkins focused on hepatobiliary malignancies and joined the faculty in 2003. 

    Dr Ahuja's surgical specialization is in management of sarcomas and complex gastrointestinal cancers, including gastric, rectal, and pancreatic cancers. She has developed an international reputation for management of peritoneal cancer metastases with cytoreduction and heated intraperitoneal chemotherapy, which attracts patients from around the world. She is a strong advocate for working with various disciplines to deliver caring and cutting edge treatment to her patients and is honored as a top doctor by multiple organizations. Prior to coming to Yale as chair of surgery, she was the director of sarcoma program and gastric cancer program.

    Dr. Ahuja is also a passionate advocate of clinician scientist and has run a laboratory focused on developing new knowledge to improve cancer outcomes. Her NIH funded laboratory has been focused on identifying new biomarkers for pancreas and colon cancers using liquid biopsies and stool DNA. She has also led over twenty national and international clinical trials on testing new therapies in gastrointestinal and breast cancers based on concepts identified in her laboratory.

    She is a national and international surgical leader and surgeon scientist who serves on multiple editorial boards and in national leadership positions including as an elected member of the National Academy of Medicine, member of the American Surgical Association, New England Surgical Society, Southern Surgical Association and on the Association of American Medical Colleges Council of Faculty and Academic Societies Administrative Board. She has published over 300 papers and book chapters contributing to both the surgical and basic science fields. Her many awards and honors include the William J. Reinhoff, Jr. Scholar Award, the American Surgical Association Fellowship, the Society of Surgical Oncology Clinical Investigator Award, and the Abell Foundation Award: Johns Hopkins Alliance for Science and Technology Development.



  • Assistant Professor of Pharmacology

    Research Interests
    • Neoplasm Metastasis

    Our lab uses multidisciplinary approaches to understand the impact of RNA metabolism in development, health and disease. We are primarily focused in identifying the physiological and pathophysiological roles of RNA modifications and non-coding RNAs at the molecular, cellular and organismal levels. Claudio, a native of Chile, obtained his Ph.D. from Cornell University in NYC. He was a postdoctoral fellow at the Rockefeller University before joining Yale University in 2017.

  • Professor of Pediatrics (Gastroenterology)

    Research Interests
    • Antidiarrheals
    • Intestinal Diseases

    I am a URM physician-scientist and Professor of Pediatrics (Gastroenterology), Cellular and Molecular Physiology at the Yale University School of Medicine. I have led an NIH-supported laboratory for over 2 decades and trained multiple undergraduate students, post-docs, medical students and research scientists, the majority of whom come from under-represented backgrounds. My research interest is focussed on mechanisms responsible for diarrheal diseases. My lab primarily investigates mechanisms regulating the CFTR chloride channel in the intestine and how these are linked to genetic, and non-genetic diarrheal diseases and Cystic Fibrosis (CF). We elucidated trafficking mechanisms regulating CFTR that are implicated in diarrhea that are the basis for successful drug therapies to treat constipation and increase intestinal fluidity (Linaclotide, Lubiprostone). Currently, we investigate kinase signaling mechanisms responsible for regulating CFTR in genetic and non genetic diarrheal diseases and CF affecting newborns and children. 

    My clinical practice is focussed on food and gut health in children to treat and prevent obesity, and chronic lifestyle diseases. We promote the use of healthy food for prevention of intestinal diseases in children, provide nutritional consultation, and design culturally sensitive diets for parents. We provide conventional standard of care along side nutritional promotion as needed, but focus on foods, exercise, stress reduction and lifestyle as a primary modalities for disease treatment and prevention. 


     

  • Professor of Pharmacology and of Molecular Biophysics and Biochemistry; Co-Leader, Developmental Therapeutics, Yale Cancer Center; Co-Director Therapeutics/Chemotherapy Program

    Research Interests
    • Molecular Biology
    • Pharmacology
    • Anti-Retroviral Agents
    • HIV Reverse Transcriptase
    • Multifunctional Enzymes

    Karen S. Anderson is a Professor of Pharmacology and Molecular Biophysics and Biochemistry. She is involved in teaching undergraduates and graduate students about drug discovery and structure-based drug design. She also serves as an undergraduate research mentor and is a fellow at Pierson College at Yale serving as a undergraduate freshman advisor. Dr. Anderson's research utilizes mechanistic enzymology and structure-based drug design. Her work focuses on understanding how enzymes, playing critical roles in such diseases as cancer and infectious diseases, including AIDS, work at a molecular level. She uses that information to develop new drug therapies. She has trained over 50 undergraduates, graduate students, M.D./Ph.D. students and postdoctoral students who have gone on to graduate school and medical school as well as successful careers in academia and industry and who are involved in biomedical research.




  • C. N. H. Long Professor of Medicine (Nephrology) and Professor of Cellular And Molecular Physiology

    Research Interests
    • Acid-Base Imbalance
    • Cell Membrane Permeability
    • Hyperoxaluria
    • Urinary Tract Physiological Phenomena
    • Water-Electrolyte Imbalance
    • Nephrolithiasis

    Dr. Aronson received his undergraduate education at the University of Rochester and his medical education at New York University. He was an internal medicine resident at the University of North Carolina and a research fellow at the National Institutes of Health before coming to Yale as a renal fellow in 1974. He was Chief of the Section of Nephrology at Yale from 1987-2002. Dr. Aronson has published articles and book chapters on the mechanisms regulating sodium, acid-base, and oxalate excretion by the kidney, particularly as related to the formation of kidney stones. He has received a number of awards for his research work, including the Young Investigator Award of the American Society of Nephrology (ASN) and American Heart Association in 1985, the Homer W. Smith Award of the ASN in 1994, election to the American Academy of Arts and Sciences in 2009, the Robert W. Berliner Award of the American Physiological Society (APS) in 2016, and the Walter B. Cannon Award of the APS in 2019. He served as President of the American Society of Nephrology in 2008. Dr. Aronson actively participates in the teaching of undergraduate, graduate and medical students, as well as residents and fellows. He was a co-recipient of the Charles W. Bohmfalk Teaching Prize in the Basic Sciences in 2005. Dr. Aronson is an Associate Director of the Yale M.D.-Ph.D. Program.

  • Professor of Therapeutic Radiology; Chief, Pediatrics Central Nervous System Radiotherapy Program, Therapeutic Radiology

    Research Interests
    • DNA Repair
    • Glioma
    • Medical Oncology
    • Pediatrics
    • Radiology
    • Therapeutics
    • Central Nervous System Neoplasms
    • Radiation Oncology
    • Genomics
    • High-Throughput Screening Assays

    Dr. Ranjit Bindra is a physician-scientist at Yale School of Medicine and Co-Director of the Yale Brain Tumor Center at Smilow Cancer Hospital. In the laboratory, his group recently led a team of four major laboratories at Yale, which reported the stunning discovery that IDH1/2-mutant tumors harbor a profound DNA repair defect that renders them exquisitely sensitive to PARP inhibitors. This work was published in Science Translational Medicine, and Nature, and it has received international attention with major clinical implications Dr. Bindra is now translating this work directly into patients, in four phase I/II clinical trials, including an innovative, biomarker-driven trial specifically targeting the Adolescent/Young Adult (AYA) cancer patient population. In addition, he is lead co-PI of a 35-site, NCI-sponsored Phase II trial testing the PARP inhibitor, olaparib, in adult IDH1/2-mutant solid tumors (NCT03212274). As a biotech entrepreneur he recently co-founded Cybrexa Therapeutics, a Series B round-funded company focused on developing an entirely new class of small molecule DNA repair inhibitors, which directly target the tumor microenvironment. Dr. Bindra received his undergraduate degree in Molecular Biophysics and Biochemistry from Yale University in 1998, and both his MD and PhD from the Yale School of Medicine in 2007. He completed his medical internship, radiation oncology residency, and post-doctoral research studies at the Memorial Sloan-Kettering Cancer Center (MSKCC) in 2012.

  • Associate Professor of Pharmacology and of Molecular Biophysics and Biochemistry

    Research Interests
    • Biochemistry
    • Crystallography
    • Molecular Biology
    • Protein Kinases
    • Substrate Specificity
    • Signal Transduction
    • Hemangioma, Cavernous, Central Nervous System

    Dr. Boggon is a structural biologist interested in the molecular basis of cytosolic signal transduction cascades. He completed his Ph.D. at the University of Manchester, U.K., and postdoctoral studies at Mount Sinai School of Medicine, Columbia University and the Dana-Farber Cancer Institute (at Harvard Medical School). His lab is interested in understanding how RhoGTPase signal transduction pathways are regulated at the molecular level, and the molecular basis for acquisition of cerebrovascular disorders.

  • Professor of Neurosurgery and of Cellular And Molecular Physiology; Co Vice Chair of Research, Neurosurgery

    Research Interests
    • Autistic Disorder
    • Central Nervous System Diseases
    • Nervous System Malformations
    • Nervous System Diseases
    • Neurologic Manifestations
    • Neurosurgery
    • Physiology
    • Stem Cells
    • Diseases

    Dr. Angélique Bordey holds the rank of Professor of Neurosurgery, and Cellular & Molecular Physiology. Dr. Bordey is an active participant in teaching and training of graduate and medical students at Yale School of Medicine. Dr. Bordey is an  Editor for several journals, including Epilepsy Currents, Glia, Neuroplasticity, Neurogenesis, Frontiers in Neuroscience, and Frontiers in Neurogenesis. She has served as a permanent and ad hoc member on several grant review committees and NIH study sections. Finally, she is a McKnight awardee and holds several federal and foundation grants .

  • Professor of Dermatology, Pathology, and Immunobiology; Co-Leader, Genetics, Genomics and Epigenetics, Yale Cancer Center; Director, Yale Center for Immuno-Oncology; Director, Yale SPORE in Skin Cancer

    Research Interests
    • Cell Biology
    • Dermatology
    • Melanoma
    • Neoplasm Metastasis
    • Pathology

    Marcus Bosenberg MD, PhD, is a physician scientist who directs a leading melanoma research laboratory, is Co-Leader of the Genomics, Genetics and Epigenetics Research Program of Yale Cancer Center, Contact PI of the Yale SPORE in Skin Cancer, Inaugural Director of the Yale Center for Immuno-Oncology, Director of the Center for Precision Cancer Modeling, and is a practicing dermatopathologist at Yale Dermatopathology through Yale Medicine.

    In his research, Dr. Bosenberg studies the genetics and cellular changes that result in melanoma, the leading cause of skin cancer deaths. His laboratory has developed several widely utilized mouse models in order to study how melanoma forms and progresses, to test new melanoma therapies, and how the immune system can be stimulated to fight melanoma. He works to translate basic scientific findings into improvements in melanoma diagnosis and therapy. He has published over 100 peer-reviewed articles, is a member of the Yale Cancer Center Executive Committee, and is a faculty member of the Raymond and Beverly Sackler Institute for Biological, Physical, and Engineering Sciences.

    Dr. Bosenberg mentors undergraduate, graduate, medical, and MD-PhD students in his laboratory, teaches at Yale School of Medicine, and trains resident physicians, fellows, and postdoctoral fellows.

  • Associate Professor of Pathology

    Research Interests
    • Calcification, Physiologic
    • Osteoarthropathy, Primary Hypertrophic
    • Pathology
    • Pseudoxanthoma Elasticum
    • Sickle Cell Trait
    • Rare Diseases
    • Vascular Calcification

    Demetrios Braddock was born in Tennessee, educated at the University of Chicago, trained at the NIH in Anatomic Pathology and Biophysical Chemistry, and came to Yale in 2004. He practices Hematopathology and leads a laboratory that studies the ENPP enzymes – a family of extracellular enzymes that create small molecules in the extracellular environment that regulate organismal homeostasis in processes such as hemostasis, bone mineralization, and vascular development. We are especially interested in a rare disease of lethal vascular calcifications called 'Generalized Arterial Calcification of Infancy' (GACI) associated with ENPP1 deficiency, and designed and validated an enzyme therapy that was curative in a mouse model of GACI. We are now moving this therapy into patients in collaboration with a company we founded (Inozyme Pharma). We have also identified a form of early onset osteoporosis associated with ENPP1 deficiency, and are investigating the role of ENPP1 in low bone mass and increased tissue calcification, a medical condition called 'Paradoxical Mineralization' which occurs in the general medical population in conditions such as aging and chronic kidney disease.

  • Waldemar Von Zedtwitz Professor of Medicine (Rheumatology) and Professor of Pathology and of Epidemiology (Microbial Diseases); Chief, Rheumatology, Allergy, & Immunology; Rheumatologist in Chief, Rheumatology

    Research Interests
    • Africa
    • Epidemiology
    • Macrophage Migration-Inhibitory Factors
    • Malaria
    • Pathology
    • Public Health
    • Rheumatology
    • Stem Cells
    • Global Health
    • Communicable Diseases, Emerging
    • Infectious Disease Medicine

    Richard Bucala, MD, PhD, is a Professor of Medicine, Pathology, and Epidemiology & Public Health.  He studies the mechanisms by which protective immune responses lead to immunopathology, focusing on MIF-family cytokines and their genetics, which his group first cloned and characterized experimentally.  Currently, his laboratory is leading multidisciplinary efforts to develop immunotherapies tailored to an individual’s genetic makeup. An anti-MIF antibody developed by the group is undergoing clinical testing in oncology, and an anti-MIF receptor antibody, recently FDA approved, is under evaluation in SLE. Dr. Bucala also is credited with the discovery of the fibrocyte, which is being targeted therapeutically in different fibrosing disorders.  He is a co-founder of Cytokine Networks and of MIFCOR, a biotechnology startup begun as a student-advised project.  Dr. Bucala was elected to the American Society for Clinical Investigation and the Association of American Physicians. He is the Editor-in-Chief of Arthritis & Rheumatology and has served on numerous advisory boards for the NIH, the pharmaceutical industry, academia, and private foundations.

  • Assistant Professor of Pharmacology

    Research Interests
    • Biochemistry
    • Biophysics
    • Electrophysiology
    • Pharmacology
    • Smell
    • Taste
    • Cryoelectron Microscopy
    • Ligand-Gated Ion Channels

    Joel received his undergraduate degree from the University of Alberta, Canada, and his Ph.D. from Columbia University. He received postdoctoral training in the MacKinnon and Ruta Laboratories at The Rockefeller University before joining the Department of Pharmacology at Yale in 2020. As a postdoc, Joel used single-particle cryo-electron microscopy to determine the first high-resolution structure of an olfactory receptor, the insect Orco. At Yale, Joel is continuing to study smell and taste receptors to elucidate the elementary principles of chemosensory detection.